SRI 31215 TFA

Cat. No.: HY-114363A

CAS No.: 1832686-44-8

Molecular Formula: $C_{27}H_{34}F_3N_5O_3$

Molecular Weight: 533.59

Target: c-Met/HGFR

Pathway: Protein Tyrosine Kinase/RTK

Storage: 4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (234.26 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.8741 mL	9.3705 mL	18.7410 mL
	5 mM	0.3748 mL	1.8741 mL	3.7482 mL
	10 mM	0.1874 mL	0.9370 mL	1.8741 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (3.90 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (3.90 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (3.90 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

SRI 31215 (TFA) is a Matriptase/Hepsin/hepatocyte growth factor activator (HGFA) triplex inhibitor and mimics the activity of HAI-1/2 (endogenous inhibitors of HGF activation). SRI 31215 has potent inhibitory activity against matriptase, hepsin and HGFA with IC_{50} values of 0.69 μM, 0.65 μM and 0.30 μM, respectively. SRI 31215 can be used for the research of cancer[1].

IC_{50} & Target

IC50: 0.69 μM (matriptase); 0.65 μM (hepsin); 0.30 μM (HGFA)[1]

In Vitro

SRI 31215 (TFA) has potent activity against matriptase, hepsin and HGFA with IC_{50} values of 0.69 μM, 0.65 μM and 0.30 μM, respectively[1].
?SRI 31215 (10 μM) inhibits the proteolytic activation of pro-HGF[1].

?SRI 31215 (10 μM, 30 min) inhibits fibroblast-induced HGF/MET signaling in tumor cells[1].
?SRI 31215 (10 μM, 24 h) inhibits fibroblast-induced epithelial mesenchymal transition (EMT) and migration in tumor cells[1].
?SRI 31215 (10 μM) overcomes the resistance to EGFR inhibitors mediated by autocrine HGF/MET signaling in colon cancer cells[1].
?SRI31215 (10 μM, 72 h) averts fibroblast-mediated resistance to EGFRi-induced apoptosis[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	DU145 cells
Concentration:	10 μM
Incubation Time:	30 min
Result:	Prevented fibroblast-induced MET activation and signaling in tumor cells, but did not prevent MET activation induced by active HGF.

Cell Migration Assay [1]

Cell Line:	DU145 cells
Concentration:	10 μM
Incubation Time:	24 h
Result:	Did not interfere with HGF-induced migration, but inhibited fibroblast-induced migration of DU145 cells.

REFERENCES

[1]. Owusu BY, et al. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. Oncotarget. 2016 May 17;7(20):29492-506.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA